DOI: https://doi.org/10.22141/2309-8147.7.1.2019.163005

Studying the vascular-endothelial growth factor level in the tears in newborns of the risk group for developing the retinopathy of prematurity

S.V. Katsan, S.G. Fedotova

Abstract


Background. The retinopathy of prematurity (ROP) is a specific pathology of premature newborns. ROP can lead to blindness, but it is predictable with early treatment. To prevent severe complications, all pediatric ophthalmologists use screening for premature newborns every 2 weeks before the retina becomes to normal condition, or the ROP appears. But every-two-week screening disturbs such babies, needs the special equipment and high skills of ophthalmologists and nurses to provide this procedure. Such features make us to look for additional ways to diagnose the ROP. Today we know the relation between the vascular-endothelial growth factor (VEGF) levels and the ROP onset. In this study, we searched the method of the ROP prediction based on changing of VEGF levels. The purpose was to find the relation between the changes of VEGF level in the tears in premature newborns of the risk group and the state of ROP. Materials and methods. The study involved 32 newborns of the risk group for the ROP (weight of birth was less than 1500 g, gestation age was under 32 weeks). At the moment of screening, we took the tears from babies. To collect the tears, we used the sterile sheet of filter paper with further freezing. The VEGF level was determined by the solid immunoassay analysis. The data obtained were statistically processed with Student’s and Wilcoxon criterions. Results. VEGF level in tears in premature newborns of the risk group for ROP was found to be higher if associated with onset or the progression of this disease. Also no changes were determined in babies with normal retina growth without ROP. Conclusions. Statistically significant increase in VEGF level in tears was found in premature babies with ROP onset or its progression.


Keywords


retinopathy of prematurity; VEGF; ROP diagnosis; premature newborns; VEGF level in tears

References


Илюхин П.А. Применение антиангиогенных факторов в хирургическом лечении пролиферативной диабетической ретинопатии: Автореф. диссертации. — М., 2012.

Левкина О.А. Транссклеральная диодная лазеркоагуляция сетчатки как первый этап хирургического лечения пациентов с пролиферативной диабетической ретинопатией: Автореф. диссертации. — М., 2010.

Патент України на корисну модель № 121473, МПК А61В 3/00 від 11.12.2017. Бюл. № 23.

Сайдашева Э.И., Сомов Е.Е., Фомина Н.В. Избранные лекции по неонатальной офтальмологии. — СПб.: Нестор-история, 2006.

Самойлов А.Н., Мустафин А.Г., Коробицын А.Н. Сосудистый эндотелиальный фактор роста в слезной жидкости как маркер эффективности лечения диабетической ретинопатии // Казанский медицинский журнал. — 2012. — № 6.

Слепова О.С., Еремеева Е.А., Рябина М.В., Сорожкина Е.С. Цитокины в слезной жидкости и сыворотке крови как ранние биомаркеры возрастной макулярной дегенерации // Медицинская иммунология. — 2015. — Т. 17, № 3. — С. 245-252.

Сыроедова О.Н. Факторы риска развития диабетической ретинопатии: Автореф. диссертации. — М., 2009.

From the Screening Examination of Premature Infants for Retinopathy of Prematurity / American Academy of Pediatrics. Policy Statement // Pediatrics. — 2013. — Vol. 131, № 1. — P. 189-195.

Hakeem A.H., Mohamed G.B., Othman M.F. Retinopathy of prematurity: A Study of Incidence and Risk Factors in NICU of Al-Minya University Hospital in Egypt // J. Clin. Neonatol. — 2012. — Vol. 1, № 2. — P. 76-81.

Jefferies A.L. Retinopathy of prematurity: Recommendations for screening / Canadian Paediatric Society // Paediatr. Child Health. — 2010. — Vol. 15, № 1. — P. 667-670.

Jingfang L., Bingyin S., Shuixiang H., Xiaoli Y., Willcox M.D.P., Zhenjun Zhao. Changes to tear cytokines of type 2 diabetic patients with or without retinopathy.

Kasza M., Balogh Z., Biro L., Ujhelyi B., Damjanovich J., Csutak A., Várdai J., Berta A., Nagy V. Vascular endothelial growth factor levels in tears of patients with retinal vein occlusion // Graefes Arch. Clin. Exp. Ophthalmol. — 2015. — Vol. 253, № 9. — P. 1581-1586.

Reddy B., Doddamani R.M., Koujalagi M.B., Guruprasad G., Ashwini R.C. Retinopathy of prematurity in a tertiary care hospital: incidence and risk factors // Pediatric Review: International Journal of Pediatric Research. — 2016. — Vol. 3, № 5.

Rentka A., Hársfalvi J., Berta A., Köröskényi K. Clinical Study: Vascular Endothelial Growth Factor in Tear Samples of Patients with Systemic Sclerosis / Hindawi Publishing Corporation // Mediators of Inflammation. — 2015.

Royal College of Paediatrics and Child Health. Guideline for the Screening and Treatment of Retinopathy of Prematurity [Электронный ресурс]. — Режим доступа: http://www.rcpch.ac.uk/improving-child-health/clinical-guidelines/find-paediatric-clinical-guidelines/neonatology/guideline

Taqui A.M., Syed R., Chaudhry T.A., Ahmad K., Salat M.S. Retinopathy of prematurity: frequency and risk factors in a tertiary care hospital in Karachi, Pakistan / Taqui A.M. // J. Pak. Med. Assoc. — 2008. — Vol. 58, № 1. — P. 186-190.

Tasman W. Retinopathy of prematurity: Do we still have a problem? The Charles L. Schepens lecture // Arch Ophthalmol. — 2011. — № 129. — P. 1083-1086.

Verma A., Nema N., Patel S., Ishrat S., Sidharth M. Retinopathy of Prematurity: Incidence and Risk Factors Research Article / Verma A. // Int. J. Ophthalmol. Eye Res. — 2016. — Vol. 4, № 3. — P. 198-201.

Vesaluoma M., Teppo A.M., Grönhagen-Riska C., Tervo T. Release of TGF-beta 1 and VEGF in tears following photorefractive keratectomy // Curr. Eye Res. — 1997. — Vol. 16, № 1. — P. 19-25.

Visser K.E., ChB M.B., BSc (MedSci) Hons, Freeman N. Retinopathy of prematurity screening criteria and work load implications at Tygerberg Children’s Hospital, South Africa: A cross-sectional study / Visser K.E. — 2016. — Vol. 106, № 6.

Zakaria N., Van Grasdorff S., Wouters K., Rozema J., Koppen C., Lion E. Human Tears Reveal Insights into Corneal Neovascularization // PLoS ONE — 2012. — Vol. 7, № 5. — P. 351-364.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта